drugset / Trial / NCT07063030
A Study of LX107 Gene Therapy in AIPL1-IRD Patients
Phase 0
Recruiting
13 enrolled
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Innostellar Biotherapeutics · collab
NaSingle-groupOpen-labelTreatment
Summary
Administering subretinal injection of LX107 injection (a gene therapy drug) to patients with retinal dystrophy caused by AIPL1 gene mutation to evaluate its efficacy and safety.
Timeline
- Start
- 2025-07-15
- Primary completion
- 2026-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LX107 | Gene therapy (AAV / viral vector) | 3e+09 vg | Other |
| Subject | LX107 | Gene therapy (AAV / viral vector) | 1e+10 vg | Other |
| Subject | LX107 | Gene therapy (AAV / viral vector) | 3e+10 vg | Other |